Catalyst
Slingshot members are tracking this event:
Cellectar Biosciences Patent Application for Phospholipid-Ether Analogs as Cancer Targeting Drug Vehicles Published by USPTO
Do you think this event is important to the companies below? How will it affect their stock price?
Related Companies | Importance
|
Impact on Stocks
|
||||
---|---|---|---|---|---|---|
CLRB | Community voting in process |
Additional Information
As previously stated, these patents will protect both composition of matter and method of use for those phospholipid drug conjugates, or PDCs, developed with Cellectar's proprietary phospholipid-ether delivery vehicle conjugated with any existing or future cytotoxic agents, including chemotherapeutics such as paclitaxel, for targeted delivery to cancer cells and cancer stem cells.
Slingshot Insights Explained
Catalyst Date
Occurred on:
May 20, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Phospholipid-ether Analogs, Cancer Targeting Drug Vehicles, Uspto, Phospholipid Drug, Phospholipid-ether Delivery Vehicle Conjugate, Future Cytotoxic Agents, Chemotherapeutics, Paclitaxel